drugset

drugset / Trial / NCT04273555

Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging

NCT04273555 ↗

Phase 1/2 Withdrawn University of Alabama at Birmingham

NaSingle-groupOpen-labelDiagnostic

Summary

The purpose of the study is to see if a new group of imaging tests can help identify response to stage IV HER2+ breast cancer before treatment.

Timeline

Start: 2026-03-01
Primary completion: 2028-06-30
Completion: 2028-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	18F-FDG	Diagnostic / imaging agent	—	—

Indications